Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00165334 · ClinicalTrials.gov registry record · Phase 2

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target
3
Study locations

NCT00165334: Completed Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Dana-Farber Cancer Institute.

NCT00165334 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 53 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00165334, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is it to determine how well patients with non-small cell lung cancer respond to cetuximab plus vinorelbine. We would also like to determine the safety of cetuximab plus vinorelbine in people 70 years of age or older with advanced non-small cell lung cancer.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Cetuximab
  • DRUG Vinorelbine (Navelbine)

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2005-06
Est. Completion 2007-11
Phase Phase 2
Dana-Farber Cancer Institute

781 total trials

What the finished NCT00165334 record still lists

NCT00165334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.

NCT00165334 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00165334 about?

NCT00165334 is a clinical study titled "Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer". The purpose of this study is it to determine how well patients with non-small cell lung cancer respond to cetuximab plus vinorelbine. We would also like to determine the safety of cetuximab plus vinorelbine in people 70 years of age or older with advanced non-small cell lung cancer.

What is the current status of trial NCT00165334?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2005-06. Estimated completion is 2007-11.

What conditions does trial NCT00165334 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT00165334?

The interventions under investigation include: Cetuximab (DRUG), Vinorelbine (Navelbine) (DRUG).

Who is sponsoring clinical trial NCT00165334?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00165334 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00165334's enrollment target sits among peer trials

53 329th of 454 higher than 126 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00165334, the US trial registry maintained by the National Library of Medicine. NCT00165334 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.